Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4181535 | L'Encéphale | 2015 | 4 Pages |
Abstract
Although negative symptoms are recognized as a central feature of schizophrenia, their definition as well as phenomenology have long been a vexing issue. During these last years, a major progress has been made with the delineation of two underlying subdomains of negative symptoms: diminished expression and anhedonia-avolition-apathy. As current guidelines are not always in accord on the efficacy of treatments on negative symptoms, it may be tempting to re-interpret the findings of clinical trials by looking at the effects of treatments on these two subdomains. This could concern both psychotropic treatments and psychotherapeutic interventions. Furthermore, neuroimaging as well as emotional response studies have permitted to better understand the mechanism which could be at the root of diminished expression and anhedonia in schizophrenia. On this basis, new psychotherapeutic methods have been devised which, by specifically targeting these two subdomains, are likely to be more efficient on negative symptoms. Further research is warranted to test their efficacy in randomized controlled trials.
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
J.-M. Azorin, M. Adida, R. Belzeaux, D. Pringuey, J.-A. Micoulaud Franchi, N. Simon, M. Cermolacce, A. Kaladjian, E. Fakra,